能倍乐 思力华噻托溴铵国内有吗

In the human airway, it has high affinity with receptors, dissociates slowly from muscarinic M1 and M3 receptors, and can block cholinergic nerve-mediated contraction of bronchial smooth muscle for a long time. However, Respimat and Tiotropium dissociate from muscarinic M2 receptors quite quickly, thus showing unique kinetic selectivity for M1 and M3 receptors.

So are Respimat, Slava, Tiotropium bromide available in China?

It is understood that tiotropium bromide, olodaterol, and repimat are already on the market in China, so patients can purchase this drug in major domestic regular pharmacies or hospital pharmacies with a prescription issued by a doctor. In some areas and covered by medical insurance, patients can consult local hospitals.

Respimat, Slivar, and Tiotropium bromide are used to treat dyspnea caused by airway obstructive diseases such as bronchial asthma, chronic bronchitis, wheezing bronchitis, and emphysema. It is especially suitable for patients who need to take long-term adrenergic β2 receptor agonists and patients with nocturnal asthma.

Preclinical in vitro and in vivo studies have shown that Tiotropium Bromide, a component of Respimat and Seriva, has a dose-dependent, site-specific blocking effect on methacholine-induced bronchoconstriction that can be sustained for up to 24 days. For more than 1 hour, the bronchodilation effect produced by inhaling tiotropium bromide is mostly a site-specific effect. Clinical studies have shown that the lung function can be significantly improved within 30 minutes of the first administration, and the pharmacodynamic steady state is reached within 1 week. Tiotropium bromide can also significantly improve the early and late peak expiratory flow rate (PEFR), and it has maintained its bronchodilator effect during the 1-year administration period without the occurrence of tolerance. In addition, dyspnea can be significantly improved.

After young healthy volunteers inhaled Respimat, Slava, and Tiotropium bromide, the absolute bioavailability was 19.5%, and food did not affect its absorption. At steady state, when patients with chronic obstructive pulmonary disease (COPD) inhale 18 mcg of this product, the plasma concentration reaches a peak value (17~19 pg/ml) in 5 minutes, and then decreases rapidly in a multi-compartment model, with the plasma trough concentration at steady state being 3~4 pg/ml. The plasma protein binding rate of this product is 72%, and the distribution volume is 32L/kg. This product cannot pass the blood-brain barrier.

Respimat, Seriva and tiotropium bromide can significantly improve patients' lung function, reduce symptoms of COPD, improve quality of life, and can effectively reduce the incidence of acute exacerbations. In addition, its original soft mist inhalation device realizes active spraying, which is easy for patients to inhale and ensures efficient lung deposition, which is conducive to ensuring the clinical efficacy of the drug.

Recommended related hot articles: /newsDetail/85205.html